GeneBioTech Price To Earning vs. Total Debt
| 086060 Stock | KRW 3,270 140.00 4.11% |
For GeneBioTech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GeneBioTech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GeneBioTech Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GeneBioTech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GeneBioTech Co over time as well as its relative position and ranking within its peers.
GeneBioTech |
GeneBioTech Total Debt vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GeneBioTech's current stock value. Our valuation model uses many indicators to compare GeneBioTech value to that of its competitors to determine the firm's financial worth. GeneBioTech Co is number one stock in price to earning category among its peers. It also is the top company in total debt category among its peers making up about 109,042,966 of Total Debt per Price To Earning. Comparative valuation analysis is a catch-all model that can be used if you cannot value GeneBioTech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for GeneBioTech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.GeneBioTech Total Debt vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
GeneBioTech |
| = | 19.69 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
GeneBioTech |
| = | 2.15 B |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
GeneBioTech Total Debt vs Competition
GeneBioTech Co is the top company in total debt category among its peers. Total debt of Health Care industry is presently estimated at about 26.33 Billion. GeneBioTech holds roughly 2.15 Billion in total debt claiming about 8% of equities under Health Care industry.
GeneBioTech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GeneBioTech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GeneBioTech will eventually generate negative long term returns. The profitability progress is the general direction of GeneBioTech's change in net profit over the period of time. It can combine multiple indicators of GeneBioTech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. The company was founded in 1984 and is headquartered in Gongju, South Korea. GeneBioTech is traded on Korean Securities Dealers Automated Quotations in South Korea.
GeneBioTech Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GeneBioTech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GeneBioTech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GeneBioTech's important profitability drivers and their relationship over time.
Use GeneBioTech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneBioTech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneBioTech will appreciate offsetting losses from the drop in the long position's value.GeneBioTech Pair Trading
GeneBioTech Co Pair Trading Analysis
The ability to find closely correlated positions to GeneBioTech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneBioTech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneBioTech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneBioTech Co to buy it.
The correlation of GeneBioTech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneBioTech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneBioTech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneBioTech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your GeneBioTech position
In addition to having GeneBioTech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in GeneBioTech Stock
To fully project GeneBioTech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of GeneBioTech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include GeneBioTech's income statement, its balance sheet, and the statement of cash flows.